Moderna, Inc.

We are mRNA. And mRNA is us.

Every day, we come together to create the blueprints needed to fight and eradicate diseases, and to help people live healthier lives. And the world has witnessed the powerful benefits of our platform technology.

With mRNA technology, we are completely reimagining how medicines are created and delivered. And in the process, we’re launching an entirely new industry, one fueled by deep care for our teams as well as for others.

Through the power of mRNA, we’re giving our people a platform to change medicine—and an opportunity to change the world.

Come with us as we pursue the uncharted reaches of possibility and make your mark on the future of medicine: modernatx.com/careers

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
200 Technology Square
Cambridge, MA
Stock Symbol: MRNA
Stock Exchange: USNASDAQ GS

  • Featured Employer

Changing the future of medicine starts with our people. Across Moderna, our colleagues are working to make the impossible possible, and our goal is to support them every step of the way. Our workforce has grown significantly over the last few years as we have rapidly scaled to become a global commercial company. With more than 5,500 people around the world, we are focused on creating an environment that is rooted in a strong sense of belonging. Hear from our changemakers.

At Moderna, our changemakers are actively building a better future, one innovation at a time. We recently asked Keke if she could create a six-word story about what being a changemaker meant to her.
We know that you will give us your all and we want to make sure that we’re doing the same for you and the people closest to you. We’re on this incredible journey of pushing past the possible together, which is why we provide paramount support for both you and your family.
NEWS
Public health officials are seeing a notable rise in cases and expressing concerns over more subvariants of the SARS-CoV-2 virus. For those stories and more, continue reading.
Gilead’s Veklury made massive profits, but as more vaccine boosters arrive and more people become immune to the virus, the future of the antiviral is in question.
Moderna has made the official request to the FDA to approve its COVID-19 for use in children ages 6 months to 5 years. Moderna also announced the location of its first non-U.S. mRNA manufacturing facility.
The U.S. Congress is calling for the coronavirus management plan to deliberate on the timeline for the approval and release of vaccines for children under 5 years old.
How many boosters are enough to protect against COVID-19 infection? This question has been at the forefront of the minds of everyone as news crops up about yearly boosters.
Noubar Afeyan, founder of Flagship Pioneering and Moderna, spoke at an event hosted by the Institute of Global Health Innovation.
With COVID-19 still very much a threat to the public, researchers are working on developing new treatments. Read on for more updates.
It was yet another busy week for clinical trial news, with a range of studies for COVID-19, various cancers, fungal infections and other indications.
Although treating patients is the top priority of the biopharma industry, there’s no doubt that money is the driver. This is a broad look at the current state of biopharma bucks.
JOBS
  • 2025 Hotbed Maps - Genetown - Elite - Moderna.png
IN THE PRESS